The OpenFold AI Research consortium welcomes 4 new members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research


DAVIS, Calif.–(BUSINESS WIRE)–OpenFold, a nonprofit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of of four new industrial members: Bayer, Dassault Systèmes, CHARM Therapeutics and BaseCamp Research Ltd.

OpenFold, a consortium of academic and industrial partners founded in February 2022, is a project of the Open Molecular Software Foundation, a nonprofit organization that advances molecular science by building communities for the development of open source research software . The four new members join OpenFold founders: Mohammed AlQuraishi’s Laboratory, Cyrus Biotechnology, Arzeda, Outpace Bio and Genentech’s Prescient Design.

Bayer of Leverkusen, Germany, is a global company with core competencies in the fields of life sciences healthcare and nutrition. Dassault Systèmes SE, of Vélizy-Villacoublay, France, develops software to create 3D virtual environments for product design, simulation and manufacturing. CHARM Therapeutics of London applies 3D deep learning technology for drug discovery and development. BaseCamp Ltd of London has created Knowledge Graph, a database of proteins of previously unknown organisms found in various natural environments, for the development of new drugs, diagnostics and agricultural products.

“This growth in membership continues the momentum generated after the formation of the consortium, as well as the introduction of the first protein structure prediction AI model published by the consortium and developed in the laboratory of Dr. Mohammed AlQuraishi, both in June of this year,” said Brian Weitzner, Ph.D. Associate Director of Computational and Structural Biology at Outpace Bio and co-founder of OpenFold.

“At Bayer, we foster innovation and transformation. We are delighted to be partners of OpenFold, where we can work with leading experts across all industries to develop the best design methodologies for pharmaceutical and agricultural products. By computationally simplifying our discovery process, we can increase the speed and quality of product design,” said Dr. Ruth Wagner, vice president, plant biotechnology data science and analytics lead at the Bayer’s Crop Science division.

“By joining the growing OpenFold community, we are excited to strengthen the use of AI in our discovery solution experiences.” Reza Sadeghi, Chief Strategy Officer BIOVIA, Dassault Systemes.

OpenFold’s mission is to bring to everyone the most powerful software ever – AI systems capable of engineering the molecules of life. These tools can be used by academics, biotech and pharmaceutical companies, or students learning how to create the drugs of tomorrow, accelerate basic biological research, and bring to market new treatments that would be impossible to discover without AI. .

About OpenFold

OpenFold is a not-for-profit artificial intelligence (AI) research consortium of academic and industrial partners whose goal is to develop free and open-source software tools for biology and drug discovery, hosted within the framework of a project of the Open Molecular Software Foundation. Membership is encouraged among biotech, pharmaceutical, biosynthetic, software/technology, and not-for-profit research organizations. For more information, please visit: OpenFold Consortium.

Join OpenFold

Press and membership inquiries should be directed to [email protected]


Comments are closed.